Skip to content

Search

Showing results for "early lung health"

April lives life in the fast lane

April Welsh lives life in top gear, literally. Diagnosed with T1D just before her 4th birthday, April became the first female to race in the Formula Vee

CGM announcement

The PMH Diabetes Clinic welcomes the recent Federal Government announcement making fully subsidised Continuous Glucose Monitoring available to young people.

Global organisation backs Strep A vaccine

A global philanthropic organisation has backed an Australian-led bid to develop a Strep A vaccine which could save millions of lives around the world.

When differently abled experiences collide, magic happens

A quality of life tool developed by disability researcher Jenny Downs is helping to reveal the difference specific interventions can make to the lives of children and families living with disability.

Injury study aims to help frontline staff better recognise domestic violence

A The Kids Research Institute Australia research student concerned by the types of injuries he was seeing in emergency departments as a trainee doctor has spearheaded an Australia-first study.

Antiviral drug shown to speed up COVID-19 recovery

An international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.

Spectrum

Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.

Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastoma

Glioblastoma, a lethal high-grade glioma, has not seen improvements in clinical outcomes in nearly 30 years. Ion channels are increasingly associated with tumorigenesis, and there are hundreds of brain-penetrant drugs that inhibit ion channels, representing an untapped therapeutic resource. The aim of this exploratory drug study was to screen an ion channel drug library against patient-derived glioblastoma cells to identify new treatments for brain cancer. 

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

Both tumour suppressive and oncogenic functions have been reported for dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Herein, we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma. Our phosphoproteomic and mechanistic studies show that DYRK1A induces degradation of cyclin B by phosphorylating CDC23, which is necessary for the function of the anaphase-promoting complex, a ubiquitin ligase that degrades mitotic proteins.

Germline Elongator mutations in Sonic Hedgehog medulloblastoma

Genetic predisposition to proteome instability may be a determinant in the pathogenesis of paediatric brain cancers